Trial reportWorld journal of urology2019
Comparison of < 100 cc prostates and > 100 cc prostates undergoing aquablation for benign prostatic hyperplasia.
Trial report in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03123250 (Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II), which is not on this map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A Systematic Review of Reported Ejaculatory Dysfunction in Clinical Trials Evaluating Minimally Invasive Treatment Modalities for BPH.Current urology reports · 2020Pooled it
- Efficacy and safety of aquablation of the prostate for patients with symptomatic benign prostatic enlargement: a systematic review.World journal of urology · 2020Pooled it
- Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2019Pooled it
- Global trends in robotic-assisted laparoscopic surgery (RALS): a bibliometric analysis (2000-2024).Updates in surgery · 2026Article
- One-month postoperative α-blocker therapy reduces morbidity and increases patients' satisfaction and well-being following water jet aquablation for treating benign prostatic obstruction: a randomized prospective trial.Central European journal of urology · 2026Article
- Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation.Prostate cancer and prostatic diseases · 2024Review
- Minimally invasive surgical therapies (MISTs) for lower urinary tract symptoms (LUTS): promise or panacea?Asian journal of andrology · 2024Review
- CUA 2022 Annual Meeting Abstracts - Podium Session 1: BPH, GU Trauma and Reconstruction, Neurogenic Bladder, Urinary Incontinence and Voiding Dysfunction, Pediatrics Friday, June 24, 2022 • 13:30-14:30.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Reasons to overthrow TURP: bring on Aquablation.World journal of urology · 2021Review
- Pharmacological and interventional treatment of benign prostatic obstruction: An evidence-based comparative review.BJUI compass · 2021Review
- A narrative review of the management of benign prostatic hyperplasia in patients undergoing penile prosthesis surgery.Translational andrology and urology · 2021Review
- WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80-cmEuropean urology open science · 2021Article
- The combination of waterjet ablation (AquabeamCentral European journal of urology · 2021Article
- Operative time comparison of aquablation, greenlight PVP, ThuLEP, GreenLEP, and HoLEP.World journal of urology · 2020Article
- [A (new) revolution in the treatment of benign prostatic hyperplasia? Aqua-ablation and prostate embolization].Der Urologe. Ausg. A · 2020Review
- The New American Urological Association Benign Prostatic Hyperplasia Clinical Guidelines: 2019 Update.Current urology reports · 2020Review
- Transfusion rates after 800 Aquablation procedures using various haemostasis methods.BJU international · 2020Article
- Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30-80 and 80-150 mL prostates.BJU international · 2020Article
- Furthering the external validity of Aquablation and implications for real-world patients.World journal of urology · 2019Article
- The Role of Aquablation for the Surgical Treatment of LUTS/BPH.Current urology reports · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSurgical options for benign prostatic hyperplasia (BPH) become limited when treating large prostates due to steep learning curves and less effective treatment. Aquablation (AquaBeam System, PROCEPT BioRobotics, Inc., USA) could remedy this. We compare the effectiveness of Aquablation in large prostates between 80 cc and 100 cc and very large prostates > 100 cc.
methodsWATER II (NCT03123250) is a prospective, multicenter, international clinical trial of Aquablation for the surgical treatment of LUTS/BPH in men of age 45-80 years with prostates between 80 cc and 150 cc. Aquablation was performed using the AquaBeam System. The reported analysis compares the subgroup of patients with a baseline prostate size of < 100 cc versus those with a prostate size of > 100 cc. Students' t test was used for continuous variables and Fisher's test for ordinal/binary variables.
resultsOf 114 screened patients, 101 meeting eligibility criteria were enrolled at 13 US and 3 Canadian sites between September and December 2017. Mean operative time was 31.2 ± 8 min in the < 100 cc subgroup and 41.7 ± 14.9 min in the > 100 cc subgroup. The average length of stay following the procedure for the < 100 cc subgroup was 1.5 ± 0.7 days versus 1.7 ± 1.1 days for the > 100 cc subgroup. Mean changes in International Prostate Symptom Score (IPSS), IPSS quality of life, and IPSS voiding and storage subscores were substantial, occurring soon after treatment and averaging (at 3 months) 16.5, 2.8, 10.6, and 5.8 points, respectively (all p < 0.0001).
conclusionAquablation clinically normalizes outcomes between patients of the < 100 cc and > 100 cc prostate cohorts. It is safe and effective in patients with large prostate glands (> 100 cc) with a smoother learning curve.
Indexed as
Identifiers
30370457What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.